Sanofi

Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Fierce Biotech
Eli Lilly
lebrikizumab
Demira
Sanofi
Regeneron
Dupixent
atopic dermatitis
Flag link:
Synthetic Antibodies to be Designed with Organoids
Synthetic Antibodies to be Designed with Organoids
Science & Enterprise
antibodies
synthetic antibodies
organoids
Prellis Biologics
Sanofi
Flag link:
Sanofi preps API spinoff for Paris exchange listing, shareholders reap dividend
Sanofi preps API spinoff for Paris exchange listing, shareholders reap dividend
Endpoints
Sanofi
API
spinoffs
Paris
EuroAPI
Flag link:
Sanofi steps off the sidelines to ink 3 ADC deal with Seagen, reigniting long-held interest in the modality
Sanofi steps off the sidelines to ink 3 ADC deal with Seagen, reigniting long-held interest in the modality
Fierce Biotech
Sanofi
Seagen
antibody-drug conjugate
cancer
oncology
Flag link:
Playing catch-up with J&J, Sanofi taps Blackstone for $300M to fund pivotal trial of subcutaneous Sarclisa
Playing catch-up with J&J, Sanofi taps Blackstone for $300M to fund pivotal trial of subcutaneous Sarclisa
Fierce Pharma
Sanofi
Blackstone Life Sciences
Sarclisa
Multiple Myeloma
Flag link:
Long wait for pivotal data on Sanofi's oral SERD ends in failure
Long wait for pivotal data on Sanofi's oral SERD ends in failure
Fierce Biotech
Sanofi
Amcenestrant
Serds
breast cancer
clinical trials
Flag link:
Sanofi Unites Under a Single Purpose at Cambridge Crossing
Sanofi Unites Under a Single Purpose at Cambridge Crossing
BioSpace
Sanofi
headquarters
Cambridge
Sanofi Pasteur
Sanofi Genzyme
Flag link:
Sanofi, scarred by Roche scrap, hits goal in once-weekly hemophilia A trial and plots race to regulators
Sanofi, scarred by Roche scrap, hits goal in once-weekly hemophilia A trial and plots race to regulators
Fierce Biotech
Sanofi
Roche
Sobi
hemophilia A
clinical trials
Flag link:
Pressing for label change, vaccine giant Sanofi takes Seqirus influenza imbroglio to the FDA
Pressing for label change, vaccine giant Sanofi takes Seqirus influenza imbroglio to the FDA
Fierce Pharma
Sanofi
Seqirus
vaccines
flu vaccines
Flag link:
Going All In on mRNA, Sanofi Breaks Ground on New Vaccine Site
Going All In on mRNA, Sanofi Breaks Ground on New Vaccine Site
BioSpace
Sanofi
vaccines
MRNA
drug manufacturing
Flag link:
Sanofi, AstraZeneca Express Optimism Over Phase III Infant RSV Results
Sanofi, AstraZeneca Express Optimism Over Phase III Infant RSV Results
BioSpace
Sanofi
AstraZeneca
nirsevimab
vaccines
RSV
clinical trials
Flag link:
Sanofi's net prices keep slipping—despite list price hikes—thanks to billions in rebates
Sanofi's net prices keep slipping—despite list price hikes—thanks to billions in rebates
Fierce Pharma
Sanofi
drug pricing
drug rebates
Flag link:
Sanofi inks an alliance pact with chronic disease-focused digital therapeutics player
Sanofi inks an alliance pact with chronic disease-focused digital therapeutics player
Endpoints
Sanofi
DarioHealth
digital therapeutics
chronic disease
Flag link:
Rare disease and neurology take outs tick higher
Rare disease and neurology take outs tick higher
EP Vantage
M&A
AbbVie
AstraZeneca
Bristol Myers Squibb
JNJ
Gilead Sciences
Jazz Pharmaceuticals
Merck
Pfizer
Sanofi
rare disease
neurology
Flag link:
Sanofi chases fourth Dupixent nod after late-stage eosinophilic esophagitis trial win
Sanofi chases fourth Dupixent nod after late-stage eosinophilic esophagitis trial win
Fierce Pharma
Sanofi
Regeneron
eosinophilic esophagitis
Dupixent
clinical trials
Flag link:
Sanofi signals a big interest in oncology as it adds a cancer R&D star to the board
Sanofi signals a big interest in oncology as it adds a cancer R&D star to the board
Endpoints
Sanofi
oncology
cancer
R&D
Antoine Yver
Centessa
Flag link:
Sanofi presses CDC experts to back its high-dose Fluzone shot for older adults
Sanofi presses CDC experts to back its high-dose Fluzone shot for older adults
Fierce Pharma
Sanofi
flu vaccines
Fluzone
CDC
ACIP
Flag link:
Sanofi and GSK ready to seek authorization for COVID-19 vaccine
Sanofi and GSK ready to seek authorization for COVID-19 vaccine
Biopharma Reporter
Sanofi
GSK
vaccines
COVID-19
clinical trials
FDA
Flag link:
Sanofi's Dupixent falls short in phase 3 chronic spontaneous urticaria trial
Sanofi's Dupixent falls short in phase 3 chronic spontaneous urticaria trial
Pharmaforum
Sanofi
Regeneron
clinical trials
Dupixent
chronic spontaneous urticaria
Flag link:
Innovent's phase 3 hits tee it up to challenge Amgen and Sanofi for Chinese PCSK9 market
Innovent's phase 3 hits tee it up to challenge Amgen and Sanofi for Chinese PCSK9 market
Fierce Biotech
Innovent Biologics
China
clinical trials
Amgen
Sanofi
Flag link:

Pages